1. Parkinsonism Relat Disord. 2023 Feb;107:105248. doi: 
10.1016/j.parkreldis.2022.105248. Epub 2022 Dec 17.

Frequency of non-motor symptoms in Parkinson's disease patients carrying the 
E326K and T369M GBA risk variants.

Usnich T(1), Olmedillas M(2), Schell N(3), Paul JJ(2), Curado F(2), Skobalj 
S(2), Csoti I(4), Ertan S(5), Gruber D(6), Zittel S(7), Sammler E(8), Isaacson 
SH(9), Kühn AA(10), Pedrosa DJ(11), Reetz K(12), Kasten M(13), Rolfs A(14), 
Bauer P(2), Skrahina V(15), Klein C(1), Brüggemann N(16); LIPAD Study Group(17).

Author information:
(1)Institute of Neurogenetics, University of Lübeck, Germany.
(2)CENTOGENE GmbH, Rostock, Germany.
(3)Institute of Neurogenetics, University of Lübeck, Germany; Department of 
Pediatrics, Universitätsmedizin Essen, Germany.
(4)Gertrudis Clinic Biskirchen, Parkinson-Center, Leun, Germany.
(5)Department of Neurology, Koç University School of Medicine, Istanbul, Turkey.
(6)Movement Disorders Clinic, Beelitz-Heilstätten, Germany.
(7)University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
(8)University of Dundee, Dundee, Scotland, UK.
(9)Parkinson's Disease and Movement Disorder Center of Boca Raton, Boca Raton, 
USA.
(10)Department of Neurology, Movement Disorders and Neuromodulation Unit, 
Charité-Universitätsmedizin Berlin, Berlin, Germany.
(11)Department of Neurology, University Hospital Marburg, Marburg, Germany.
(12)Department of Neurology, University Hospital Aachen, Aachen, Germany.
(13)Institute of Neurogenetics, University of Lübeck, Germany; Department of 
Psychiatry and Psychotherapy, University of Lübeck, Germany.
(14)CENTOGENE GmbH, Rostock, Germany; University of Rostock, Albrecht Kossel 
Institute, Rostock, Germany; Arcensus GmbH, Rostock, Germany.
(15)CENTOGENE GmbH, Rostock, Germany; Arcensus GmbH, Rostock, Germany.
(16)Institute of Neurogenetics, University of Lübeck, Germany; Department of 
Neurology, University of Luebeck, Luebeck, Germany. Electronic address: 
norbert.brueggemann@neuro.uni-luebeck.de.
(17)Institute of Neurogenetics, University of Lübeck, Germany; Department of 
Neurology, University of Luebeck, Luebeck, Germany.

DOI: 10.1016/j.parkreldis.2022.105248
PMID: 36565535 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of competing interest TU, NS, IC, 
SE, DG, ES, SHI, AAK, DJP, KR, MK report no conflict of interest. MO, AR, VS at 
the time of the study were employed by CENTOGENE GmbH. AR and VS are currently 
employed by Arcensus GmbH. JJP, FP, SS and PB are employed by CENTOGENE GmbH. SZ 
reports consultancies to Biomarin, receiving honoraria from Merz and Biomarin, 
and receiving funding from German Research Foundation and European Union; CK 
reports Medical advisor role to CENTOGENE GmbH for genetic testing of movement 
disorders excluding Parkinson's disease, and to Retromer Therapeutics; NB 
received honaria from Abbott, Abbvie, Biogen, Biomarin, Bridgebio, Centogene and 
Zambon.